Early and often: reimagining patient community engagement to improve clinical trials feasibility
Parexel is proud to have collaborated with Global Genes on the whitepaper “Early and Often: Reimagining Patient Community Engagement to Improve Clinical Trials Feasibility”. In this report, you'll discover compelling findings that emphasize the critical importance of engaging patient advocacy organizations early and often to accelerate trial success while reducing costs and eliminating barriers.
This comprehensive white paper underscores how involving patient communities from the outset of clinical trial design can fundamentally transform trial outcomes. In this report, you'll discover compelling findings that emphasize the critical importance of engaging patient advocacy organizations early and often.
By adopting a patient-centric strategy, companies can accelerate trial success while reducing costs and eliminating barriers. This is more than a report—it’s a call to action for the biopharmaceutical industry to rethink its approach to rare disease clinical trials.
Related Insights
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Blog
Greater empathy, greater efficiency: How patient-first clinical development benefits all of us
Sep 10, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Blog
Do we still need broad patient representation in breast cancer trials? Absolutely.
Oct 17, 2025
Audiogram
New FDA regulatory initiatives improving rare disease drug development
Sep 23, 2025
Related Insights
Blog
Hope Interrupted: Why Even Short Gaps in Rare Disease Treatment Matter More Than We Think
Jun 23, 2026
Blog
Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression
Apr 23, 2024
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Blog
Parexel names first Patient Ambassador
Jun 17, 2022
Blog
Greater empathy, greater efficiency: How patient-first clinical development benefits all of us
Sep 10, 2026
Blog
Japan: the new strategic launchpad for accelerating global rare disease development
Jul 23, 2026
Blog
A Deep Dive into the Genetic Therapies Bootcamp at the ACMG 2026 Annual Meeting
Jun 23, 2026
Blog
Faster access for rare disease patients starts with smarter alignment
Jun 22, 2026
CTB Blog
Shaping a competitive, patient-centered future for Europe: Insights from the EURORDIS Round Table of Companies
Mar 5, 2026
Blog
Do we still need broad patient representation in breast cancer trials? Absolutely.
Oct 17, 2025
Audiogram
New FDA regulatory initiatives improving rare disease drug development
Sep 23, 2025